Alzamend Neuro, Inc.
NCM: ALZNLive Quote
About Alzamend Neuro, Inc.
Healthcare
Biotechnology
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
📊 Fundamental Analysis
Alzamend Neuro, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -250.0%, which indicates that capital utilization is currently under pressure.
At a current price of $0.86, ALZN currently trades near the bottom of its 52-week range (0%), indicating potential value or weakness (Range: $0.85 - $8.22).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$4.38M
Trailing P/E
--
Forward P/E
-0.33
Beta (5Y)
-0.05
52W High
$8.22
52W Low
$0.85
Avg Volume
145K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App